文献速递血栓与止血

胶质母细胞瘤不同致癌程序细胞群释放平足蛋白作为促凝胞外囊泡

Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.
PubMed 文献 · Blood Adv · 2021-01-01

该研究通过单细胞和 bulk 转录组数据挖掘及细胞与小鼠异种移植模型,分析胶质母细胞瘤中表达平足蛋白(PDPN)的细胞亚群及其对凝血和血小板活化的影响。发现 PDPN 由特定的间充质样 GBM 细胞亚群表达,并受 EGFR 和 IDH1 致癌突变及表观遗传改变下调;胶质瘤细胞以胞外囊泡(EVs)形式释放 PDPN 和/或组织因子(TF),PDPN-EVs 激活血小板,TF-EVs 激活凝血级联,两者共表达协同促进肿瘤微血栓形成。

要点

  • GBM 中间充质样细胞亚群表达 PDPN,其表达受 EGFR/IDH1 突变及表观遗传调控。
  • 胶质瘤细胞通过 EVs 释放 PDPN 和 TF,分别激活血小板和凝血级联。
  • PDPN 与 TF 共表达协同促进肿瘤微血栓形成,或为抗血栓干预靶点。

核心结论

  • GBM 中不同细胞亚群通过释放携带 PDPN 或 TF 的 EVs 驱动癌症相关血栓形成的多个方面。

研究设计与样本

  • 研究采用单细胞和 bulk 转录组数据挖掘,以及细胞实验和小鼠异种移植模型。

主要发现

  • PDPN 由特定的间充质 GBM 细胞亚群表达,并受 EGFR 和 IDH1 致癌突变以及染色质修饰和 DNA 甲基化改变下调。
  • 胶质瘤细胞在体外和体内以 exosome 样 EVs 形式外化 PDPN 和/或 TF。
  • 注射 PDPN-EVs 激活血小板,而 TF-EVs 激活凝血级联。
  • 在相应胶质瘤异种移植小鼠中,分别表达 PDPN 或 TF 的肿瘤导致血小板活化标志物(血小板因子 4)或凝血标志物(D-二聚体)升高。
  • GBM 细胞共表达 PDPN 和 TF 协同影响肿瘤微血栓形成。

临床怎么用

  • PDPN 和 TF 及其 EVs 可能作为 GBM 相关血栓的诊断标志物和抗血栓干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vascular anomalies, including local and peripheral thrombosis, are a hallmark of glioblastoma (GBM) and an aftermath of deregulation of the cancer cell genome and epigenome. Although the molecular effectors of these changes are poorly understood, the upregulation of podoplanin (PDPN) by cancer cells has recently been linked to an increased risk for venous thromboembolism (VTE) in GBM patients. Therefore, regulation of this platelet-activating protein by transforming events in cancer cells is of considerable interest. We used single-cell and bulk transcriptome data mining, as well as cellular and xenograft models in mice, to analyze the nature of cells expressing PDPN, as well as their impact on the activation of the coagulation system and platelets. We report that PDPN is expressed by distinct (mesenchymal) GBM cell subpopulations and downregulated by oncogenic mutations of EGFR and IDH1 genes, along with changes in chromatin modifications (enhancer of zeste homolog 2) and DNA methylation. Glioma cells exteriorize their PDPN and/or tissue factor (TF) as cargo of exosome-like extracellular vesicles (EVs) shed from cells in vitro and in vivo. Injection of glioma-derived podoplanin carrying extracelluar vesicles (PDPN-EVs) activates platelets, whereas tissue factor carrying extracellular vesicles (TF-EVs) activate the clotting cascade. Similarly, an increase in platelet activation (platelet factor 4) or coagulation (D-dimer) markers occurs in mice harboring the corresponding glioma xenografts expressing PDPN or TF, respectively. Coexpression of PDPN and TF by GBM cells cooperatively affects tumor microthrombosis. Thus, in GBM, distinct cellular subsets drive multiple facets of cancer-associated thrombosis and may represent targets for phenotype- and cell type-based diagnosis and antithrombotic intervention.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tawil N, Bassawon R, Meehan B, et al. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Adv. 2021. PMID: 33720339. doi:10.1182/bloodadvances.2020002998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。